Aim The aim was to develop and validate a scoring system for the assessment of chronic pain on quality of life (QoL) following surgical treatment of rectal cancer (RC).
Introduction
In 2015, an estimated 1.65 million new cases of colorectal cancer (CRC) were diagnosed worldwide, making it the third most prevalent cancer [1] . On current projections, the global burden of CRC is expected to increase to 2.2 million new cases yearly by 2030 [2] . Rectal cancer (RC) accounts for about one-third of all CRC. Survival rates of RC have greatly improved in recent years and are now higher than for colon cancers [3] .
Curative treatment for RC usually comprises a combination of surgical resection and neoadjuvant therapy. The most commonly performed surgical procedures are anterior resection (AR), with total or partial mesorectal excision, abdominoperineal excision (APE) and Hartmann's operation [4] [5] [6] [7] [8] [9] .
Increased life expectancy of cancer survivors emphasizes the importance of long-term outcomes. Bowel, sexual and urinary dysfunction have been well described [10] [11] [12] [13] [14] . Recently, the LARS score was developed to standardize reporting of low anterior resection syndrome (LARS) and provide clinicians with a convenient tool for assessing post-resectional bowel dysfunction [15] . Few investigations addressing the role of chronic pain (CP) have been carried out.
Chronic post-surgical pain (CPSP) is a well recognized complication following surgical procedures [16, 17] . A study found that 31% of RC patients experienced CPSP and that the pain was associated with a reduced quality of life (QoL) [18] .
Comparison of results between studies necessitates a uniform standard for measuring CP after resectional treatment for RC. No common terminology or method of assessment currently exists. Ideally, terminology should include both pain frequency and presentation.
This aim of this study was to develop and validate a simple and easy-to-use scoring system for the assessment of CP on QoL following treatment for RC. Our objective was to develop a score that would identify pain that impacted upon QoL.
Method Participants and questionnaire data acquirement
This study included all patients diagnosed with adenocarcinoma of the rectum in the period May 2001-December 2014 found in the Danish Colorectal Cancer Group's database. This database contains detailed information on patients and treatment and is complete for 98.6% of all entries [2] . Patients who survived more than 18 years were identified by crosslinking the data with the Danish civil registration system. These patients were sent comprehensive questionnaires regarding bladder, sexual and bowel function and CP, as well as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire -Core 30 (EORTC QLQ-30). Informed consent was obtained. Only data relating to pain and QoL are presented in this study.
Participants
Patients who had not undergone resection/excision surgery or had evidence of disseminated or recurrent disease were excluded.
Pain questionnaire
Patients were asked if they experienced CP in the abdomen, pelvis or lower extremities, and whether this pain developed during or after treatment. If they answered 'no' to any of these questions, they were instructed not to answer further items and were assigned a score value of 0. The remaining patients were to complete the pain questionnaire, with results used in statistical analysis to isolate items relevant for QoL impact of pain.
The CP questionnaire used in this study was based on a selection from a 21-item questionnaire previously used in our group; this questionnaire is described in detail elsewhere [18] . In brief, the 21 items concerned pain location, intensity, character, duration, functional aggravation, perception of causation, use of analgesia and other treatment, disturbance of night's sleep, lumbar disc herniation and abandoned activities due to pain.
Based upon results from the previous study, 10 factors were deemed clinically irrelevant (two concerning perception of causation, two concerning analgesia, four concerning pain in other parts of the body and two concerning lumbar disc herniation) and were removed from this study. Additionally, three questions regarding localization were combined into one. We added four questions relating to pain intensity during daily routines and physical exertion. Each individual question was analysed for the association with impaired QoL using an 'anchor term'. This was as follows: 'Overall, to what extent does your pain influence your QoL?' Options given were 'not at all', 'a little', 'some' and 'a lot'.
Thus, a total of 13 questions regarding pain were included in our final questionnaire.
Development and validation

Randomization
The eligible patients were randomized into one of two groups of approximately equal size stratified for age, sex, radiochemotherapy and minimally invasive or open approach. One group was used for score development, including item selection, numerical value assignment and categorization cut-off values, while the other group was used for validation.
Development group item selection
The four options of the anchor question were analysed as required for regression analyses. The resulting groups of minor and major impact of QoL were made by combining 'not at all' with 'a little' and 'some' with 'a lot', depending on answer distribution. The 13 items, each containing two to five response options, were correlated with QoL impact using the anchor question in the development group. Associations were computed using logistic regression analyses. Items with significant associations were included for further analysis in a multivariate model. Multivariate analyses were carried out to calculate adjusted odds ratios (aORs) for each item correcting for the other independent variables. Items with statistically significantly increased aORs were selected for the score. Answers were summarized into two to three options depending on the distribution of answers and crude ORs.
Development group score values
Each selected item's response options were assigned an aOR-dependent value to allow for an additive model. The values of each patient's responses were added together for a final score value.
Development group categorization
For appropriate classification of patients and ease of use, the score needed to be categorized based on the numerical value range correlated with QoL impact. Three classification groups were generated corresponding to the reduction of the four anchor question QoL impact options to three: the option 'not at all' corresponded to the score category 'no significant pain', 'a little' to 'minor pain syndrome' and 'some' was combined with 'a lot' to correspond to 'major pain syndrome'. Subsequent to development and validation, patients with a score of 0 (no CPSP) were included in the no significant pain group. Receiver operating characteristic (ROC) curves of score value vs QoL impact groups were used to identify interim cut-off points between the three score categories to be confirmed during validation. For each of the three categories, the values with most favourable specificity and sensitivity were chosen. As the main aim of the score was to identify CP patients with potential QoL impact, sensitivity was valued higher than specificity.
Validation of the score
The validity of the selected items and score categorization was tested on the other half of the population. To test score difference between the three QoL impact groups, median values, standard deviations and confidence intervals were calculated together with a Kruskal-Wallis test.
To assess the score's ability to predict the effect of pain on QoL, ROC curves of the score vs the three groups of no, minor and major impact were analysed to compute the sensitivity and specificity of the score and to compare cut-off points to those calculated for the 18 860 diagnosed with RC.
11 608 met exclusion criteria. 1 -3196 had not received resection.
-1793 had disseminated disease.
-4561 dead / declared mentally imcompetent.
-37 died after participant identification.
-21 reports of unregistered mental impairment by next of kin. 7252 eligible patients.
2293 did not wish to participate.
4959 patients included.
Pain after treatment
Randomized to score development n = 1072
Randomized to score validation n = 856
No pain after treatment In cases where multiple exclusion criteria were relevant, participants were counted to the first criterion of the given order.
Colorectal Disease ª 2018 The Association of Coloproctology of Great Britain and Ireland. 21, 90-99 development group. Differences between the three groups were tested using the Kruskal-Wallis test. The prediction model was tested with a 3-by-3 table of score group vs QoL group by assessing percentages of perfect fit, moderate fit and no fit.
EORTC questionnaire
The EORTC QLQ-30 is a questionnaire of 30 items, making up five functional scales (physical, role, cognitive, emotional and social functioning), three symptom scales (fatigue, pain and nausea and vomiting), one global scale as well as several individual items [19] . The global and functional scales each span 0-100 points, with a high score indicating a high level of functioning. Only the functional scales and the global scale were used in this study. Differences in EORTC QLQ-30 between score groups were analysed using the Kruskal-Wallis test.
Risk factors for pain
Based on previous studies [18] , we hypothesized that women, younger patients, those with low tumours (close to the anal verge) and patients who had received radiochemotherapy or been treated with APE would have a higher risk of developing pain. Multivariate logistic regression analyses were carried out, computing aORs for no significant pain vs minor/major pain syndrome and no significant pain vs major pain syndrome for each factor.
Statistical analysis
All statistical analyses were done using STATA 13 (StataCorp LP, College Station, Texas , USA) with a threshold of significance of 5%.
Results
Participation
A total of 18 860 RC patients were identified, of whom 13 890 had undergone surgical resection. Of these, 6638 met the exclusion criteria (Fig. 1) . A total of 4959 out of the 7252 remaining eligible patients (68.4%) accepted participation and returned informative answers (Table 1) .
Of the 4959 responders, 1928 (38.88%) admitted to CP in the pelvic area or lower extremities which had developed at or following their surgery. Respondents with pain displayed some statistically significant differences from those without pain, although the clinical significance may be questionable. They were significantly younger (mean age at procedure 61.6 years compared to 58.9, P < 0.001), were less likely to be women (39.58% vs 43.61%, P < 0.001) and more likely to have received open approach (51.82% vs 45.92%, P < 0.001).
Of the eligible pain patients, 1072 were selected to the development group by stratified randomization, while 856 were selected for score validation ( Table 2 ).
Development of score values for CPSP patients
Eleven items were identified during the univariate analysis as meeting the criteria for inclusion in the multivariate analysis. Five of these did not retain significantly increased ORs when adjusting for independent variables. The remaining six items related to pain frequency, common intensity, intensity when most severe, duration, disruption of night's sleep and giving up daily activities.
In cases where an item's options had identical or similar aORs, options were combined for ease of use. The numeric scoring value for the items' options was found by multiplying the logarithmic value of each item's aOR by 10 and rounding. The maximum score values for each item were then added together for a maximal pain score of 45 (Table 3) .
Using ROC curves, the interim limits categorizing the score into three groups were as follows: 0-7 for no significant pain, 8-17 for minor pain syndrome and ≥18 for major pain syndrome. 
Validation of the score
A cut-off value of 18 was adopted to identify patients with a major impact on QoL. This was based on the ROC curve (Fig. 2) [area under the curve 0.8794 with high sensitivity (83.20%) and specificity (76.90%)]. A cut-off value of 8 was adopted to distinguish between patients with no and minor impact on QoL (area under the curve 0.7709; sensitivity and specificity 72.73% and 68.65%, respectively). The 3-by-3 prediction model (Table 4) showed perfect fit in 63.91% of patients, moderate fit in 34.67% and no fit in 1.42%. The score values were different across the three groups (P > 0.001, Kruskal-Wallis test; Fig. 3 ). Only patients placed in the development and validation groups for analysis were included, excluding patients without CPSP from the no significant pain group, to avoid overestimation of validity.
Final score
The final score consisted of six items with options assigned numerical values from 0 to 12, a total range of 0-45 and three classification groups (Table 6 ).
EORTC QLQ-30 analysis
There was a significant difference for the major pain syndrome group for all six investigated EORTC scales by classification group (P < 0.001; Fig. 4) . The largest differences between the no significant pain and major Figure 2 Receiver operating characteristic curve showing relationship between score value and major impact on quality of life.
pain syndrome groups were in the global score (41.66), followed by the role functioning and social functioning scales (33.33).
Risk factors
Female sex, young age, open approach and radio (chemo)therapy were identified as significant risk factors (Table 5) , with age < 50 being most significant (OR = 4.50 for placing in minor/major pain syndrome, 3.78 for major pain syndrome exclusively). Resection by APE returned increased OR but was not statistically significant (P = 0.25 for no significant pain vs major pain syndrome).
Discussion and conclusions
The results of this study suggest that our scoring system is effective in identifying CP which impacts on QoL. The score concisely comprises six patient-reported outcome measures, with values corresponding to the impact on patients' QoL with a score range of 0-45 (Table 6 ). We have also produced a classification system which enables patients to be categorized into three groups based on their accumulated score value: no significant pain (0-7), minor pain syndrome [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and major pain syndrome (≥ 18). The no significant pain group consists of patients with little QoL impact and few pain symptoms as well as patients with no CPSP (although these were excluded from development and validation analyses). These patients differ from CPSP patients by scoring 0. A 0 score would theoretically be attainable for a CPSP patient. The lowest CPSP patient score in this study (n = 1928) was 2.
Despite narrow score ranges for the no significant pain and minor pain syndrome groups, respectively, 28.54% and 34.32% of patients in the validation group belonged to these groups (Table 4) . Score ranges therefore do not correlate with patient spread but rather distinguish three functionally different groups by outcome. This functionally significant classification is key to the central aim of practical application. Patients were well fitted to these groups by QoL impact: 98.58% of patients classified as either perfect fit or moderate fit (disregarding patients without CPSP, as these were by definition perfectly fit). Sensitivity and specificity were 82.20% and 76.90% for the cut-off between minor pain syndrome and major pain syndrome groups. Sensitivity was valued over specificity, as undiagnosed pain patients with poor QoL would pose a bigger issue than falsely diagnosed patients with no pain and fair QoL; such patients can simply opt out of treatment. The QoL analysis showed large differences between the no significant pain and major pain syndrome groups. The differences between the no significant pain and minor pain syndrome groups were subtler and, although not statistically significant for all scales, they may be clinically significant.
The multivariate logistic regression analyses found that the strongest association with QoL impact was the question of pain intensity during everyday life. This was followed by questions relating to disruption of night's sleep and duration of pain. The weakest associations related to localization of pain and functional aches such as pain during meals, micturition and defaecation. High intensity transient pain or pain specific to a certain situation had less impact than consistent pain of lower intensity.
Feddern et al. [18] associated CPSP in RC patients with poor QoL especially in women, younger patients, patients receiving APE and those with prior radio (chemo)therapy. Our results corroborate these findings to an extent; while APE patients did have higher ORs for placing in either the minor or major pain syndrome group, these did not prove significant in this larger study population (Table 5) . Also, we did not find tumour distance from the anal verge to be a consistent risk factor.
Data were obtained from all RC patients in Denmark from May 2001 to December 2014, yielding a representative cohort with 7252 eligible responders. Informative answers were obtained from 68%, making it possible to randomize large numbers of participants into either the development or the validation group. As such, selection bias was reduced and generalizability validly tested. Previous methods of assessing pain include the McGill Questionnaire and the Pain Quality Assessment Scale. These are generic and do not account for QoL. As the perception of pain intensity may not increase linearly, linear grading methods are limited in application. Furthermore, it is relevant that different population groups may differ in what they regard as significant factors affecting QoL.
This study has some limitations. First, pain is a common, unspecific symptom; while all patients used for analysis declared that their pain developed either at or after treatment, recall bias may have influenced their recollection and influenced the results. The questionnaire itself was non-validated, although it was based on results from an earlier study [18] . The cohort excluded patients with recurrent or disseminated disease which might skew results. Finally, the questionnaire responders differed from the non-responders concerning age, sex, median follow-up time, surgical approach and procedure, American Society of Anesthesiologists (ASA) score and T stage.
To date, the score has only been tested on a Danish population, using the Danish language. Application to other populations would necessitate careful translation [20, 21] , to ensure linguistic and semantic equivalence. The impact of a given factor may differ between countries, as the impact of pain on QoL varies in different cultures [22, 23] . This score has only been validated on patients with RC but theoretically it could be tried on colon and other pelvic malignancies to determine whether a common score for these related cancers is possible.
Previous studies have established a significant incidence of functional issues in this group of patients [14, 15, 24, 25] , as well as CP [18] . This study has corroborated reports of appreciable prevalence of CPSP in this patient group and demonstrated that CP constitutes a considerable risk for reduced QoL. Prospective studies might be able to assess the relative importance of these functional issues and CP.
The study follows the same general principles and statistical methods as those used for development of the validated LARS score by Emmertsen and colleagues [15, 26, 27] . This method has been applied to other studies with reliable results [28] , and it is now frequently employed to permit the rapid assessment of patients in the outpatient setting. It is hoped that the scoring system reported in this study for patients with RC will achieve similar results and also facilitate comparison of outcomes from different centres.
